<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02201693</url>
  </required_header>
  <id_info>
    <org_study_id>P130302</org_study_id>
    <secondary_id>2013-A01473-42</secondary_id>
    <nct_id>NCT02201693</nct_id>
  </id_info>
  <brief_title>Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease</brief_title>
  <acronym>CD-HOPE</acronym>
  <official_title>Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GETAID Pediatric</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate of first relapse at 12 months between&#xD;
      maintenance therapy with cyclic exclusive enteral nutrition (EEN) (at least 100% daily&#xD;
      calories) and maintenance therapy with supplementary enteral nutritional support (25% daily&#xD;
      calories).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enteral nutrition (EN) is a highly efficacious treatment option for Crohn's disease (CD). In&#xD;
      children, exclusive EN is considered first choice therapy to induce remission in pediatric&#xD;
      CD, as highlighted in the recent ESPGHAN-ECCO guidelines. Several meta-analyses showed that&#xD;
      the anti-inflammatory potential of EEN is comparable to the effects of steroids. In addition,&#xD;
      children with CD often have marked growth retardation and EEN is one of the most efficacious&#xD;
      treatment options to induce catch-up growth in these patients. There is convincing data&#xD;
      indicating that EN is highly efficacious when given on an exclusive basis, while the use of&#xD;
      partial EN is markedly less effective to induce remission in active Crohn's disease as&#xD;
      compared to exclusive EN. Recently, it was suggested that exclusive EN has a dominant effect&#xD;
      on the intestinal microbiota, which contributes to the induction of remission. There exists&#xD;
      several strategies to maintain remission in children with CD, but there is no clear consensus&#xD;
      on which maintenance treatment to follow. There are some indicators to believe that enteral&#xD;
      nutritional therapy might play also a significant role as maintenance therapy for CD. Given&#xD;
      the fact that many centers use a top-down approach with the introduction of immunosuppressors&#xD;
      and/or biologics at/or shortly after diagnosis, the investigators wanted to test the&#xD;
      possibility of a treatment option to efficiently maintain remission with less (or no) side&#xD;
      effects based on enteral nutrition to avoid the early use of immunosuppressors.&#xD;
&#xD;
      It's a French multicenter, prospective, randomized study with PROBE (prospective randomized&#xD;
      open blind end-point) evaluation. Randomization will be performed in a blinded and&#xD;
      centralized manner, allocating patients to one of the two treatment groups :&#xD;
&#xD;
        -  ARM A : Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks&#xD;
&#xD;
        -  ARM B: MODULEN IBD supplementation (25% of caloric requirements) alone&#xD;
&#xD;
      A Physician not involved in the study design and blinded to the treatment arm will perform&#xD;
      the evaluation of the patients during each study visit.&#xD;
&#xD;
      A total of four visits (including final visit) are scheduled for this trial over a period of&#xD;
      12 months at a rhythm of every three months (+/- 2 weeks) for all patients. The study visit&#xD;
      will happen during scheduled routine visits, necessary for the routine care of CD patients.&#xD;
      Each visit comprises a routine clinical evaluation. The assessment of maintenance of&#xD;
      remission is particularly important (wPCDAI&lt;12.5 points), a routine lab analysis including&#xD;
      fecal calprotectin is required at each visit. In addition, all relevant medical or other&#xD;
      events will be recorded. Only for patients who participate in the annex studies an additional&#xD;
      stool sample (microbial analysis) is required. At M9 visit, follow-up endoscopy (M12+/-&#xD;
      6weeks) and entero-MRI (M12+/- 6 weeks) will be programmed as part of the routine&#xD;
      surveillance of patients on maintenance therapy, allowing to adjust treatment in the&#xD;
      following if necessary. Compliance to treatment will be monitored by recordings of daily&#xD;
      MODULEN IBD intake during 2 week periods on the E-system. A quality of life E-questionnaire&#xD;
      will be filled out one day prior to each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2014</start_date>
  <completion_date type="Actual">October 2, 2019</completion_date>
  <primary_completion_date type="Actual">October 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The first relapse</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed with wPCDAI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed with wPCDAI, CDAI, PGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first relapse</measure>
    <time_frame>until month 12</time_frame>
    <description>Assessed with wPCDAI, CDAI, PGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of wPCDAI,</measure>
    <time_frame>until month12</time_frame>
    <description>Assessed with wPCDAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>month 12</time_frame>
    <description>CDEIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmural healing</measure>
    <time_frame>Month 12</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>until month12</time_frame>
    <description>Fecal sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life analysis</measure>
    <time_frame>Until Month 12</time_frame>
    <description>E-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth pattern</measure>
    <time_frame>Until Month 12</time_frame>
    <description>Z-Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Cyclic exclusive MODULEN IBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MODULEN IBD supplementation (25% of caloric requirements)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MODULEN IBD</intervention_name>
    <description>2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).</description>
    <arm_group_label>Cyclic exclusive MODULEN IBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MODULEN IBD</intervention_name>
    <description>25% of daily caloric requirements, approx. 500mL/day</description>
    <arm_group_label>MODULEN IBD supplementation (25% of caloric requirements)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6-18 years&#xD;
&#xD;
          -  Confirmed Crohn's disease (L1, L2, L3+/- L4a/b)&#xD;
&#xD;
          -  new-onset disease or acute relapse treated with enteral nutrition&#xD;
&#xD;
          -  responding to induction therapy with exclusive enteral nutrition with complete&#xD;
             clinical remission at inclusion visit (wPCDAI&lt;12.5)&#xD;
&#xD;
          -  completed cycle of induction therapy of at least 6 weeks (6-12 weeks)&#xD;
&#xD;
          -  biological treatment by Remicade has to be stopped at least 8 weeks prior to inclusion&#xD;
&#xD;
          -  &quot;wash out&quot; of corticosteroids, immunosuppressors and treatment by Humira of minimally&#xD;
             4 weeks prior to inclusion&#xD;
&#xD;
          -  5-ASA and derivates have to be stopped at least at screening visit&#xD;
&#xD;
          -  Antibiotics must be stopped at least 2 weeks prior to inclusion&#xD;
&#xD;
          -  Informed and signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with B2 or B3 disease behavior (intestinal/colonic stenosis (including&#xD;
             ileo-caecal valve), intrabdominal abscess, fistulizing disease)&#xD;
&#xD;
          -  Patients not in remission on induction therapy (wPCDAI&gt;12.5)&#xD;
&#xD;
          -  Patients with isolated and severe perianal disease&#xD;
&#xD;
          -  Patients requiring surgical therapy at inclusion&#xD;
&#xD;
          -  Ongoing steroid medication&#xD;
&#xD;
          -  Ongoing immunosuppressor or biologics therapy&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Currently participating or having participated in another interventional clinical&#xD;
             trial during the last 4 weeks prior to the beginning of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck RUEMMELE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H么pital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease,</keyword>
  <keyword>pediatric GETAID (Therapeutic study group of inflammatory bowel diseases of the child),</keyword>
  <keyword>enteral nutrition,</keyword>
  <keyword>randomized multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

